Testing for prostate and colorectal cancer: comparison of self-report and medical record audit

被引:99
作者
Hall, HI
Van Den Eeden, SK
Tolsma, DD
Rardin, K
Thompson, T
Sinclair, AH
Madlon-Kay, DJ
Nadel, M
机构
[1] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA
[2] Kaiser Permanente No Calif, Oakland, CA 94611 USA
[3] Kaiser Permanente Georgia, Atlanta, GA 30326 USA
[4] HealthPartners, Bloomington, MN 55425 USA
关键词
screening; prostate cancer; colorectal cancer; medical audit; prostate-specific antigen; occult blood; sigmoidoscopy; colonoscopy; endoscopy;
D O I
10.1016/j.ypmed.2004.02.024
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Self-reported data are often used to determine cancer screening test utilization, but self-report may be inaccurate. Methods. We interviewed members of three health maintenance organizations and reviewed their medical records for information on digital rectal exam (DRE), prostate-specific antigen (PSA) test, fecal occult blood test (FOBT), sigmoidoscopy, and colonoscopy (response rate 65%). We calculated the sensitivity, specificity, concordance, and kappa statistic to compare the two sources for black men (n = 363), white and other men (n = 847), and women (n = 920) by study location. Results. For DRE, FOBT, sigmoidoscopy, and colonoscopy, testing rates determined by self-report were higher than those in medical records. Kappa statistics showed fair to good agreement (0.40-0.80) for PSA, sigmoidoscopy, and colonoscopy among most subgroups. For DRE and FOBT, the agreement was poor except among participants from one HMO. Sensitivity was greater than or equal to80% for sigmoidoscopy among most subgroups, and greater than or equal to85% for endoscopy (sigmoidoscopy and colonoscopy), >75% for DRE, and greater than or equal to63% for PSA among all subgroups. Specificity exceeded 80% for FOBT and colonoscopy among all subgroups. Agreement was lower among older age groups. For all tests, agreement was poor between the reasons for testing. Conclusion. Overreporting for some cancer tests should be considered when using self-reported data to evaluate progress towards reaching national goals for prevention behaviors. Published by The Institute For Cancer Prevention and Elsevier Inc.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 31 条
  • [1] *AM CANC SOC, 2003, 500803 AM CANC SOC
  • [2] [Anonymous], 2000, Vital Health Stat 2, P1
  • [3] [Anonymous], UND IMPR HLTH OBJ IM
  • [4] Baier M, 2000, CANCER EPIDEM BIOMAR, V9, P229
  • [5] Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P193
  • [6] MEASURING THE USE OF MAMMOGRAPHY - 2 METHODS COMPARED
    DEGNAN, D
    HARRIS, R
    RANNEY, J
    QUADE, D
    EARP, JA
    GONZALEZ, J
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (10) : 1386 - 1388
  • [7] Fleiss GL, 1981, STAT METHODS RATES P
  • [8] Fulton-Kehoe D, 1992, Public Health Rev, V20, P233
  • [9] A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER
    GANN, PH
    HENNEKENS, CH
    STAMPFER, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04): : 289 - 294
  • [10] GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105